Monthly Prescribing Reference

FDA: Vial Caps of Two Neuromuscular Blocking Agents May Not Have Warning Statement

The Food and Drug Administration (FDA) is notifying healthcare professionals regarding the temporary absence of the “paralyzing agent” warning statement on vial caps of vecuronium bromide for ...
Medscape

New Guidance on Recalls of Polymyxin B, Vecuronium

January 13, 2012 — The US Food and Drug Administration (FDA) yesterday issued an updated guidance on voluntary product recalls involving Bedford Laboratories injection drugs that were initially made ...
Monthly Prescribing Reference

Glass Particulate Identified in Certain Vials of Vecuronium Bromide

Vecuronium Bromide, a neuromuscular blocker, is indicated as adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ...
FiercePharma

Bedford Laboratories™ Issues Guidance on 2011 Voluntary Recall of Polymyxin B for Injection USP and Vecuronium Bromide for Injec

BEDFORD, Ohio, Jan. 10, 2012 /PRNewswire/ -- Bedford Laboratories™ today issued updated guidance on the following nationwide voluntary product recalls originally issued on August 2, 2011: Lot 1942980 ...
Medscape

Lot of Vecuronium Bromide Under Recall

July 5, 2012 — One lot of 20-mg vials of injectable Vecuronium Bromide for Injection Preservative Free (Bedford Laboratories) is being recalled because of evidence of particulate matter in some of the ...
FiercePharma

Sagent Pharmaceuticals Launches Vecuronium Bromide For Injection

SCHAUMBURG, Ill., Aug. 18, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of vecuronium bromide for injection, a neuromuscular blocking agent, in 10 and ...